ID   T24/DDP7
AC   CVCL_Y183
DR   CGH-DB; 9114-4
DR   Wikidata; Q54971459
RX   PubMed=8205547;
RX   PubMed=14973057;
RX   PubMed=29732388;
CC   Population: Caucasian; Swedish.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
CC   Derived from sampling site: Urinary bladder.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 20-05-21; Version: 10
RX   PubMed=8205547;
RA   Kotoh S., Naito S., Yokomizo A., Kumazawa J., Asakuno K., Kohno K.,
RA   Kuwano M.;
RT   "Increased expression of DNA topoisomerase I gene and collateral
RT   sensitivity to camptothecin in human cisplatin-resistant bladder
RT   cancer cells.";
RL   Cancer Res. 54:3248-3252(1994).
RX   PubMed=14973057; DOI=10.1158/0008-5472.CAN-3263-2;
RA   Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A.,
RA   Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J.;
RT   "Alteration in copy numbers of genes as a mechanism for acquired drug
RT   resistance.";
RL   Cancer Res. 64:1403-1410(2004).
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).